Headlines

FDA OKs Novartis Prostate Cancer Treatment, Triples Eligible Patient Pool

FDA approves Novartis’ Pluvicto for advanced prostate cancer patients who have received ARPI therapy.

read more

Join the newsletter

Subscribe to get our latest content by email.

    We respect your privacy. Unsubscribe at any time.

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    What would make this website better?

    0 / 400